fluphenazine enanthate Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1214 2746-81-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fluphenazine enanthate
  • moditen enanthate
  • prolixin enanthate
  • Molecular weight: 549.70
  • Formula: C29H38F3N3O2S
  • CLOGP: 7.86
  • LIPINSKI: 2
  • HAC: 5
  • HDO: 0
  • TPSA: 36.02
  • ALOGS: -5.86
  • ROTB: 14

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
March 15, 1967 FDA APOTHECON

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Schizophrenia indication 58214004 DOID:5419
Psychotic disorder indication 69322001
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.85 Basic
pKa2 3.85 Basic
pKa3 2.72 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 9.27 PDSP CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 7.42 PDSP
5-hydroxytryptamine receptor 5A GPCR Ki 6.84 PDSP
D(3) dopamine receptor GPCR Ki 9.61 PDSP
Alpha-1B adrenergic receptor GPCR Ki 7.89 PDSP
Histamine H1 receptor GPCR Ki 7.68 PDSP
5-hydroxytryptamine receptor 7 GPCR Ki 8.10 PDSP
Sodium-dependent serotonin transporter Transporter Ki 5.23 PDSP
5-hydroxytryptamine receptor 1E GPCR Ki 6.27 PDSP
5-hydroxytryptamine receptor 2C GPCR Ki 6.05 PDSP
5-hydroxytryptamine receptor 2A GPCR Ki 7.98 PDSP
5-hydroxytryptamine receptor 1B GPCR Ki 6.48 PDSP
5-hydroxytryptamine receptor 1D GPCR Ki 6.48 PDSP
Histamine H2 receptor GPCR Ki 6.25 PDSP
D(1B) dopamine receptor GPCR Ki 7.89 PDSP
D(4) dopamine receptor GPCR Ki 7.44 PDSP
D(1A) dopamine receptor GPCR Ki 7.68 PDSP
Muscarinic acetylcholine receptor M3 GPCR Ki 5.84 PDSP
Alpha-2C adrenergic receptor GPCR Ki 7.54 PDSP
Alpha-2B adrenergic receptor GPCR Ki 7.09 PDSP
Muscarinic acetylcholine receptor M1 GPCR Ki 5.96 PDSP
Alpha-2A adrenergic receptor GPCR Ki 6.50 PDSP
Muscarinic acetylcholine receptor M5 GPCR Ki 6.45 PDSP
5-hydroxytryptamine receptor 1A GPCR Ki 6.84 PDSP
Muscarinic acetylcholine receptor M4 GPCR Ki 5.27 PDSP
Alpha-1A adrenergic receptor GPCR Ki 8.19 PDSP
Muscarinic acetylcholine receptor M2 GPCR Ki 5.14 PDSP

External reference:

IDSource
4017724 VUID
N0000179195 NUI
D00792 KEGG_DRUG
4017724 VANDF
C0066682 UMLSCUI
CHEBI:5125 CHEBI
CHEMBL1200951 ChEMBL_ID
C017610 MESH_SUPPLEMENTAL_RECORD_UI
QSB34YF0W9 UNII
3389 PUBCHEM_CID
DB00623 DRUGBANK_ID
30129 RXNORM
3882 MMSL
4749 MMSL
001475 NDDF
111125005 SNOMEDCT_US

Pharmaceutical products:

None